Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Gastroesophageal Junction

Overview

The purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for Siewert II ,III of locally advanced HER-2 negative adenocarcinoma at gastroesophageal junction.

Full Title of Study: “Prospective, Randomized, Controlled, Multicenter, Phase III Study of Apatinib Plus Concurrent Neoadjuvant Chemoradiotherapy for Siewert II ,III of Locally Advanced HER-2 Negative Adenocarcinoma at Gastroesophageal Junction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 30, 2020

Interventions

  • Drug: Apatinib Capecitabine Oxaliplatin
    • apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w
  • Drug: Capecitabine Oxaliplatin
    • Preoperative: Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w

Arms, Groups and Cohorts

  • Experimental: A(apatinib Xelox)
    • Preoperative: apatinib 250mg qd po q4w Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy:45Gy/25f (1.8Gy/f/d,5 f/w) Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 2 cycles
  • Active Comparator: B(Xelox)
    • Preoperative: Capecitabine 1000mg/m2 bid d1-14,Oxaliplatin 130 mg/m2 Ivgtt d1 q3w Radiotherapy:45Gy/25f (1.8Gy/f/d,5 f/w) Postoperative: Capecitabine 1000mg/m2 bid d1-14 q3w 6 cycles

Clinical Trial Outcome Measures

Primary Measures

  • The pathological complete response rate(pCR)
    • Time Frame: [ Time Frame: within 3 weeks after surgery ]
    • The lesion disappeared completely by pathology
  • Disease-free survival(DFS)
    • Time Frame: [ Time Frame: 3 year ]
    • Baseline to measured date of recurrence or death from any cause

Secondary Measures

  • Objective response rate (ORR)
    • Time Frame: [ Time Frame: Preoperative ]
    • Baseline to measured stable disease
  • Disease Control Rate(DCR)
    • Time Frame: [ Time Frame: Preoperative ]
    • Baseline to measured disease progression
  • R0-resection rate
    • Time Frame: [ Time Frame: within 3 weeks after surgery ]
    • There was no residual by the microscope
  • Overall survival (OS)
    • Time Frame: [ Time Frame: 3years ]
    • Baseline to measured date of death from any cause

Participating in This Clinical Trial

Inclusion Criteria

1. Adult patients (18 to 70 years old) at the time of voluntarily signing informed consent; 2. Histologically or cytologically confirmed adenocarcinoma. The her-2 negative was detected by immunohistochemistry or fluorescence in situ hybridization; 3. Confirmed to Siewert II , III of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter ≤8 cm by gastroscopy; 4. Patients with Stage for Ⅲ by CT/MRI (According to the eighth edition of AJCC ); 5. Patients with measurable lesions(measuring≥10mm on spiral CT scan, satisfying the criteria in RECIST1.1); 6. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1; 7. Life expectancy greater than or equal to 6 months; 8. Subject must meet all of the following criteria based on the laboratory tests within 14 days prior to the first dose of study treatment. (1) Baseline blood indicators meet the following criteria:HB≥80g/L;ANC≥1.5×109/L;PLT≥90×109/L;WBC≥4.0×109/L and ≤15×109/L (2) Baseline biochemical indicators meet the following criteria: ALT and AST≤2.5ULN, but<≤5ULN if the transferanse elevation is due to liver metastases; ALP≤2.5ULN;TBiL≤1.5ULN;Cr≤1.5ULN,Endogenous creatinine clearance rate ˃60 ml/min (Cockcroft-Gault formula);APTT≤1.5ULN,and INR or PT≤1.5ULN. 9.Women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 7 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. Men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks; 10.Participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. Exclusion Criteria:

1. Allergic to apatinib, capecitabine and oxaliplatin; 2. The cytological examination of the abdominal cavity washing fluid showed that the tumor shedding cells were positive; 3. Have high blood pressure and antihypertensive drug treatment can not control (systolic blood pressure > 140 mmHg,diastolic blood pressure > 90 mmHg),Uncontrolled coronary heart disease and arrhythmia,classⅢ-Ⅳcardiac insufficiency; 4. A variety of factors influencing oral drugs (such as unable to swallow, nausea,vomiting,chronic diarrhea and intestinal obstruction, etc); 5. Patients with tendency of gastrointestinal bleeding, including the following:a local active ulcerative lesions,and defecate occult blood;Has melena and hematemesis in two months; 6. Coagulant function abnormality (INR > 1.5 ULN, APTT > 1.5 ULN), with bleeding tendency; 7. Pregnant or lactating women; 8. Patients with other malignant tumors within 5 years (except for curable skin basal cell carcinoma and cervical carcinoma in situ); 9. History of psychiatric drugs abuse and can't quit or patients with mental disorders; 10. Less than 4 weeks from the last clinical trial; 11. The researchers think inappropriate.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Hebei Medical University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Qun Zhao, Surgical director – Hebei Medical University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.